EMAIL THIS PAGE TO A FRIEND

AAPS PharmSciTech

Experimental and computational studies of physicochemical properties influence NSAID-cyclodextrin complexation.


PMID 24718709

Abstract

The objective of this research was to investigate physicochemical properties of an active pharmaceutical ingredient (API) that influence cyclodextrin complexation through experimental and computational studies. Native β-cyclodextrin (B-CD) and two hydroxypropyl derivatives were first evaluated by conventional phase solubility experiments for their ability to complex four poorly water-soluble nonsteroidal anti-inflammatory drugs (NSAIDs). Differential scanning calorimetry was used to confirm complexation. Secondly, molecular modeling was used to estimate Log P and aqueous solubility (S o) of the NSAIDs. Molecular dynamics simulations (MDS) were used to investigate the thermodynamics and geometry of drug-CD cavity docking. NSAID solubility increased linearly with increasing CD concentration for the two CD derivatives (displaying an AL profile), whereas increases in drug solubility were low and plateaued in the B-CD solutions (type B profile). The calculated Log P and S o of the NSAIDs were in good concordance with experimental values reported in the literature. Side chain substitutions on the B-CD moiety did not significantly influence complexation. Explicitly, complexation and the associated solubility increase were mainly dependent on the chemical structure of the NSAID. MDS indicated that each NSAID-CD complex had a distinct geometry. Moreover, complexing energy had a large, stabilizing, and fairly constant hydrophobic component for a given CD across the NSAIDs, while electrostatic and solvation interaction complex energies were quite variable but smaller in magnitude.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

284785
(S)-(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, 98%
C14H14O3
F8514
Flurbiprofen, cyclooxygenase inhibitor
C15H13FO2
F0285200
Flurbiprofen, European Pharmacopoeia (EP) Reference Standard
C15H13FO2
PHR1499
Flurbiprofen, Pharmaceutical Secondary Standard; Certified Reference Material
C15H13FO2
PHR1004
Ibuprofen, Pharmaceutical Secondary Standard; Certified Reference Material
C13H18O2
1335508
Ibuprofen, United States Pharmacopeia (USP) Reference Standard
C13H18O2
I0020000
Ibuprofen, European Pharmacopoeia (EP) Reference Standard
C13H18O2
Y0000881
Ibuprofen for peak identification, European Pharmacopoeia (EP) Reference Standard
C13H18O2
K1751
Ketoprofen, ≥98% (TLC)
C16H14O3
K2012
Ketoprofen, meets USP testing specifications
C16H14O3
1356632
Ketoprofen, United States Pharmacopeia (USP) Reference Standard
C16H14O3
K2000000
Ketoprofen, European Pharmacopoeia (EP) Reference Standard
C16H14O3
34016
Ketoprofen, VETRANAL, analytical standard
C16H14O3
PHR1375
Ketoprofen, Pharmaceutical Secondary Standard; Certified Reference Material
C16H14O3
N8280
Naproxen, meets USP testing specifications
C14H14O3
46482
Naproxen, VETRANAL, analytical standard
C14H14O3
PHR1040
Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material
C14H14O3
N0250000
Naproxen, European Pharmacopoeia (EP) Reference Standard
C14H14O3
1457301
Naproxen, United States Pharmacopeia (USP) Reference Standard
C14H14O3